Mobile

Study to investigate the effect of the A1 agonist capadenoson on ventricular HR in patients with persistent or permanent atrial fibrillation by administration of capadenoson in a dose of 4 mg once dai...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-003619-30

Study to investigate the effect of the A1 agonist capadenoson on ventricular HR in patients with persistent or permanent atrial fibrillation by administration of capadenoson in a dose of 4 mg once daily for five days

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Primary objective of the study is to investigate the effect of capadenoson (BAY 68-4986) 4 mg granulate once daily for 5 days on rate control in patients with atrial fibrillation in comparison to baseline. The reduction of HR will be assessed in a 24 h long term ECG as well as during an exercise tolerance test (ETT).

Critère d'inclusion

  • Atrial fibrillation

Liens